Provided by Tiger Trade Technology Pte. Ltd.

Alnylam Pharmaceuticals

219.72
-11.4600-4.96%
Post-market: 219.720.00000.00%17:07 EDT
Volume:1.66M
Turnover:369.74M
Market Cap:29.32B
PE:39.10
High:231.36
Open:231.31
Low:219.40
Close:231.18
52wk High:495.55
52wk Low:197.81
Shares:133.43M
Float Shares:133.16M
Volume Ratio:1.37
T/O Rate:1.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.62
EPS(LYR):2.33
ROE:96.55%
ROA:12.34%
PB:21.65
PE(LYR):94.30

Loading ...

Alnylam Pharmaceuticals Q2 Adj. EPS $1.84 Beats $1.55 Estimate, Sales $1.291B Miss $1.323B Estimate

Benzinga Earnings
·
Jul 30

Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress

THOMSON REUTERS
·
Jul 30

Alnylam Pharmaceuticals Q2 Operating Income USD 231.441 Million

THOMSON REUTERS
·
Jul 30

Alnylam Pharmaceuticals Q2 Adjusted EPS USD 1.84 VS. Ibes Estimate USD 1.55

THOMSON REUTERS
·
Jul 30

Earning Preview: Alnylam Pharmaceuticals Q2 revenue is expected to increase by 101%, and institutional views are mostly bullish

Earnings Agent
·
Jul 24

Alnylam Pharmaceuticals is Maintained at Overweight by JP Morgan

Dow Jones
·
Jul 22

Alnylam Pharma (ALNY) Gets a Buy from Oppenheimer

TIPRANKS
·
Jul 22

U.s. Research Roundup-danaher, Gm, Msci

Reuters
·
Jul 22

Alnylam Pharmaceuticals (ALNY) Could Be 39% Below Fair Value As Alzheimer’s Pipeline Progresses

Simply Wall St.
·
Jul 18

Movement Alert|Alnylam Pharmaceuticals Falls 5.04% in Regular Trading, Trading at $268.73

Market Focus
·
Jul 18

Press Release: Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results

Dow Jones
·
Jul 16

Alnylam Schedules Conference Call on Second-quarter 2026 Results

Reuters
·
Jul 16

Alnylam Initiates Phase 2 Trial of Mivelsiran in Down Syndrome-associated Alzheimer’s Disease

Reuters
·
Jul 15

Alnylam Pharmaceuticals' Q2 Results to Determine 2026 Revenue Outlook, BofA Securities Says

MT Newswires Live
·
Jul 14

Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), Madrigal Pharmaceuticals (MDGL) and Krystal Biotech (KRYS)

TIPRANKS
·
Jul 14

BofA Securities Cuts Alnylam Pharmaceuticals Price Target to $410 From $460, Maintains Buy Rating

MT Newswires Live
·
Jul 14

Alnylam Pharmaceuticals is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jul 13

Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), Vera Therapeutics (VERA) and Alnylam Pharma (ALNY)

TIPRANKS
·
Jul 13

Movement Alert|Alnylam Pharmaceuticals Falls 5.29% in Regular Trading, Trading at $281.53

Market Focus
·
Jul 13

Alnylam price target lowered to $410 from $505 at Truist

TIPRANKS
·
Jul 13